James Sapirstein, CEO of AzurRx BioPharma, Inc. talks about AZRX’s products and therapies.
Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!
See the full episode at: https://newtothestreet.com/new-to-the-street-may-16-american-premium-water-winners-inc-innerscope-hearing-technologies-zk-international-azurrx-biopharma-simplicity-esports-and-gaming-paypolitan-petprodu
James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc. (NASDAQ: AZRX), talks about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #AzurRx
